About
Our Science
News & Media
Careers
Contact Us
Urinary Cancer Test
JP
/
EN
About
Vision, Mission, and Values
Message from the CEO
Corporate Overview
Leadership Team
Company Name & Logo
Access / Location
Our Science
Cancer Detection
SMA/SCID
Bio-AI
Clinical Studies
Publications
News & Media
All
Press
Research
Media
Award
News
Careers
Contact Us
News & Media
All
→
Press
→
Research
→
Media
→
Award
→
News
All
Press
Craif Raises $33M to Accelerate Introduction of Its Urine-Based Cancer Test to the U.S.
Series D, Co-led by Granite-Integral and Diagnostics Maker Tauns, Funds a Prospective Pancreatic Cancer Study and Expansion of U.S. Clinical Team Under New Chief Medical Officer Nick Bevins
2026.08.18
Media
Craif CEO Ryuichi Onose Appears on the Unreasonable Stories Podcast
2026.05.17
Research
Craif’s Urinary MicroRNA Study Demonstrates Early Detection, Prognostic Stratification, and Lung Cancer Recurrence Monitoring, Published in
npj Precision Oncology
2026.04.30
Research
Craif Presents Collaborative Research on Urinary MicroRNA-Based Early Detection and Prognostic Stratification in Lung Cancer at the AACR Annual Meeting 2026
2026.04.30
Press
Craif Refreshes Brand Identity as It Enters Its Next Phase of Global Expansion
2026.04.24
Press
Craif Opens Bio-AI Laboratory in San Diego, U.S.
2026.04.24
Press
Craif Appoints Takeo Mukai as CFO Through Local U.S. Hire ~ Driving Non-Linear Growth of Craif's Global Business with Extensive Experience Leading Exits as CEO/COO/CFO Across Multiple U.S. Healthcare Companies ~
2026.04.24
Research
Cancer Signals Reach Urine, Often at Higher Concentrations Than Blood: Study Identifies the Mechanism for the First Time
2026.02.24
Press
Craif's Urine-Based Cancer Risk Test miSignal Is Now in More Than 2,000 Medical Institutions in Japan
2026.02.20
Research
Urinary MicroRNA and AI Separated Pancreatic Cancer from High-Risk Patients with an AUC of 0.89
2026.01.28
1
2
3
4
5
Last
News & Media
All
→
Press
→
Research
→
Media
→
Award
→
News
